HYPERTENSION, β-BLOCKERS AND ERECTILE DYSFUNCTION

• Autor(a) principal: Pinto, Ana Maria
• Data de Publicação: 2022
• Outros Autores: Freitas, Hugo, Carretas, Pedro, Marques, Rui
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.58043/rphrc.36

Objective: The purpose of this study was to characterise the population with erectile dysfunction (ED) according to their cardiovascular risk factors. To evaluate therapeutic options in the treatment of hypertension. Elaboration of recommendations to improve this integrated consultation. Methods: All patients with ED were selected from the hospital data base and followed in Sexual Health outpatient clinics during the year 2016. Results:135 patients were followed up at the Sexual Health clinic in 2016 for ED. 29 patients (21.48%) were aged less than or equal to 50 years. Of the total number of patients, 71 patients (52.59%) had hypertension. Of these, 8 patients (11.27%) took β-blockers, 6 of which were cardio selective. 21 patients (29.58%) were on ACE inhibitors. 16 patients (22.54%) were on diuretics. 4 patients (5.63%) took ACE inhibitors + diuretics combined. 8 patients (11.27%) took Angiotensin II receptor blockers (ARBs) + diuretics. 15 patients (21.13%) took calcium channel blockers (CCB). 8 patients (11.27%) took ACE inhibitors + CCB and 5 patients (7.04%) were taking ARBs + CCB. Conclusion: The prevalence of hypertension in patients with ED is high (52.6%). There are a large number of patients taking diuretics, ACE inhibitors and β-blockers which are therapeutic options to avoid. Of patients treated with β-blockers, Nebivolol was only used in 3 out of 8 patients.